Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 18;31(1):19-27.

The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool

Marc A Judson  1 , Ulrich Costabel, Marjolein Drent, Athol Wells, Lisa Maier, Laura Koth, Hidenobu Shigemitsu, Dan A Culver, Jeffrey Gelfand, Dominique Valeyre, Nadera Sweiss, Elliott Crouser, Adam S Morgenthau, Elyse E Lower, Arata Azuma, Mami Ishihara, Shin-Ichiro Morimoto, Tetsuo Tetsuo Yamaguchi, Noriharu Shijubo, Jan C Grutters, Misha Rosenbach, Hui-Ping Li, Paola Rottoli, Yoshikazu Inoue, Antje Prasse, Robert P Baughman, The Wasog Sarcoidosis Organ Assessment Instrument Investigators
Affiliations
  • PMID: 24751450

The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool

Marc A Judson et al. Sarcoidosis Vasc Diffuse Lung Dis. .

Abstract

Introduction: A Case Control Etiology of Sarcoidosis Study (ACCESS) sarcoidosis organ assessment instrument has been used for more than a decade to establish uniform standards for the probability of sarcoidosis organ involvement. The ACCESS instrument has become increasingly outdated as new technologies have been developed. Furthermore, the ACCESS instrument failed to address all possible organs involved with sarcoidosis. For these reasons, the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) developed a new sarcoidosis organ assessment instrument.

Methods: Clinical sarcoidosis experts assessed various clinical manifestations for the probability of sarcoidosis organ involvement. Two criteria were required to apply this assessment: 1) histologic evidence of granulomatous inflammation of unknown cause in an organ that was not being assessed; 2) the clinical manifestation being addressed required that alternative causes other than sarcoidosis had been reasonably excluded. Clinical manifestations were assessed as either: a) highly probable: likelihood of sarcoidosis causing this manifestation of at least 90%.; b) probable: likelihood of sarcoidosis causing this manifestation of between 50 and 90%; c) possible: likelihood of sarcoidosis causing this manifestation of less than 50%. The sarcoidosis experts voted on the likelihood of sarcoidosis causing each manifestation using Delphi study methodology where at least 70% agreement of the experts was needed for consensus.

Results: Various clinical manifestations were classified as highly probable, at least probable, possible, or indeterminate when no consensus could be reached.

Conclusion: An instrument was developed by expert opinion that may be useful for the clinician and researcher in establishing criteria for sarcoidosis organ involvement.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

LinkOut - more resources